Differentiating SIADH from Cerebral Salt Wasting in Neurologic Patients

Diagnostic Principles

• Physical examination alone is insufficient to determine extracellular fluid volume status, showing only 41 % sensitivity and 80 % specificity; objective measures are required. 1
• Misclassification leads to harmful outcomes: fluid restriction in cerebral salt wasting (CSW) can precipitate cerebral infarction, whereas volume expansion in SIADH can worsen hyponatraemia. 2

Initial Laboratory Work‑up for Serum Sodium < 131 mmol/L

• Measure serum osmolality to exclude pseudohyponatraemia caused by hyperglycaemia or hypertriglyceridaemia. 2
• Obtain urine osmolality and urine sodium concentrations. 2
• Check serum uric acid level as part of the differential. 1
• Assess thyroid function and cortisol to rule out hypothyroidism and adrenal insufficiency. 2
• Perform a comprehensive volume assessment using objective tools rather than relying on physical exam alone. 1

Objective Volume‑Status Determination

• Central venous pressure (CVP) < 6 cm H₂O suggests CSW; CVP 6–10 cm H₂O favours SIADH. 1
• Fractional excretion of sodium (FENa) and fractional excretion of urea: low values predict responsiveness to saline in hypovolaemia (CSW). 1
• An elevated blood urea nitrogen‑to‑creatinine ratio indicates volume depletion and supports CSW. 2

Laboratory Features Distinguishing SIADH and CSW

• All table entries are derived from the cited neurosurgical literature. [2][1]

Diagnostic Maneuvers

• Isotonic saline challenge: administer 0.9 % saline and observe plasma sodium change. An increase ≥ 5 mmol/L indicates CSW; lack of response suggests SIADH. 1
• Urinary sodium < 30 mmol/L after saline has a 71–100 % positive predictive value for saline responsiveness (i.e., CSW). 1

Treatment Recommendations

SIADH (euvolemic)

• Implement fluid restriction to ≤ 800 mL/day. [3][1]
• Use demeclocycline, lithium, or loop diuretics as second‑line agents when fluid restriction is insufficient. 3
• Reserve hypertonic saline for severe neurological symptoms (e.g., seizures, coma). 2
• Avoid fluid restriction in subarachnoid haemorrhage (SAH) patients at risk for vasospasm. 3

Cerebral Salt Wasting (hypovolemic)

• Provide aggressive sodium and volume replacement (50–100 mL/kg/day). 1
• Use hypertonic saline (3 %) for severe symptoms or when serum sodium falls below 120 mmol/L. 4
• Administer fludrocortisone, especially in SAH patients, to promote sodium retention. [3][5]
• Give hydrocortisone to prevent natriuresis in SAH. [3][5]
• Monitor central venous pressure to guide adequacy of volume repletion. 1

Safety Limits for Sodium Correction

• Do not exceed a rise of 10 mmol/L in serum sodium over any 24‑hour period in chronic hyponatraemia. [4][5]
• Limit correction to ≤ 1 mmol/L per hour, except in acute severe symptomatic cases where faster correction may be justified. 6
• Target a serum sodium of approximately 131 mmol/L; full normalization is unnecessary and may increase risk. 5
• Exceeding these limits raises the risk of osmotic demyelination syndrome (central pontine myelinolysis). [4][5]

Common Pitfalls

• ADH levels are not reliable for distinguishing SIADH from CSW and should not be used diagnostically. [2][1]
• Natriuretic peptide measurements have conflicting data and are not recommended for this differentiation. 2
• Apparent euvolemia on physical exam does not exclude CSW; objective volume assessment is essential. 1
• In SAH patients, hyponatraemia ≥ 131 mmol/L warrants treatment, and fluid restriction is contraindicated due to vasospasm risk. [3][5]

Management of Symptomatic Hyponatremia in Neurological Patients

Immediate Treatment

• Hypertonic 3 % saline should be given immediately to any patient with neurological symptoms (e.g., seizures, altered mental status, confusion, lethargy) caused by hyponatremia, without waiting for a definitive etiologic diagnosis. 7
• The total rise in serum sodium must be limited to ≤ 8 mmol/L in any 24‑hour period to prevent osmotic demyelination syndrome. 7

Safety Limits

• In chronic hyponatremia (> 48 h), correction should not exceed 1 mmol/L per hour; exceeding this rate markedly raises the risk of osmotic demyelination (central pontine myelinolysis). 8

Distinguishing SIADH from Cerebral Salt Wasting (CSW)

• Correctly differentiating SIADH (euvolemic) from CSW (hypovolemic) is critical because fluid restriction—appropriate for SIADH—can precipitate cerebral infarction in CSW, whereas volume expansion—appropriate for CSW—can worsen hyponatremia in SIADH. 7

SIADH Management (Euvolemic)

• First‑line therapy is fluid restriction to ≤ 800 mL per day. 7
• Hypertonic 3 % saline is reserved exclusively for patients with severe neurological manifestations (e.g., seizures, coma, marked altered mental status). 7
• If fluid restriction fails, second‑line agents such as demeclocycline, lithium, or loop diuretics may be employed. 7
• In subarachnoid hemorrhage patients at risk for vasospasm, fluid restriction should be avoided; hypertonic saline is preferred to maintain euvolemia. 7

CSW Management (Hypovolemic)

• Aggressive sodium and volume replacement of 50–100 mL/kg per day is recommended. 7
• Fludrocortisone 0.1 mg three times daily can be used to promote sodium retention, particularly in subarachnoid hemorrhage patients. 7

Treatment Priorities and Pitfalls

• Administration of hypertonic saline must never be delayed in symptomatic patients while diagnostic work‑up is ongoing; treatment takes precedence. 7
• Normal saline (0.9 % NaCl) should not be used to treat SIADH because it can act as a hypotonic solution in this setting and may paradoxically worsen hyponatremia after an initial rise. 7